Page 3 of 28

In the Claims

Docket No.: 74.US2.PCT

Please amend the claims according to the claim listing provided below.

Marked-Up Copy of Claims:

1. (Original) A compound of Formula I:

$$Ar^1$$
 R^1
 R^2
 S
 A^1
 R^2
 S
 A^2
 R^2

or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:

Ar¹ is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl optionally substituted by one or more R^{13} , heterocyclyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkyl optionally substituted by one or more R^{13} , heterocyclylalkenyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally su

Ar² is aryl or heteroaryl, each optionally substituted with one or more substituents selected from halo, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, carbocyclyl optionally substituted by one or more R¹⁴, heterocyclyl optionally substituted by one or more R¹⁴, hydroxylamino, OR⁹, SR⁹, SOR¹⁰, SO₂R¹⁰, COR¹⁰, COOR⁹, OC(O)R¹⁰ or NR¹¹R¹²;

D is N, C or CR³;

--- is a single bond when D is N or CR³;

<u>---</u> is a double bond when D is C;

 A^1 is absent or a C_{1-3} straight-chain aliphatic group optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, (C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, hydroxy, carboxy, (C_{1-4} alkoxy)carbonyl, or cyano;

Page 4 of 28

 A^2 is C_{1-4} straight-chain aliphatic group optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-6}$ alkyl)amino, hydroxy, carboxy, $(C_{1-4}$ alkoxy)carbonyl, or cyano;

Docket No.: 74.US2.PCT

E is CO, C(O)O, C(O)NR⁴, NR⁴CONR⁴, SO, SO₂, SONR⁴, SO₂NR⁴, or a bond;

G is C_{1-3} alkylene, C_{2-3} alkenylene or C_{2-3} alkynylene optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di $(C_{1-4}$ alkyl)amino, hydroxy, carboxy, $(C_{1-4}$ alkoxy)carbonyl, or cyano;

 R^1 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^1 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)aminocarbonyl, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfinyl, C_{1-4} haloalkylsulfinyl, aminosulfonyl, aminosulfonyl, (C_{1-4} alkyl)aminosulfonyl, di(C_{1-4} alkyl)aminosulfonyl, ureido, C_{1-4} alkylureido, di(C_{1-4} alkyl)ureido, thioureido, C_{1-4} alkylthioureido, di(C_{1-4} alkyl)thioureido, carboxy, (C_{1-6} alkoxy)carbonyl, and hydroxylamino;

 R^2 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^2 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)aminocarbonyl, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfinyl, C_{1-4} haloalkylsulfonyl, aminosulfonyl, (C_{1-4} alkyl)aminosulfonyl, di(C_{1-4} alkyl)aminosulfonyl, ureido, C_{1-4} alkylureido, di(C_{1-4} alkyl)ureido, thioureido, C_{1-4} alkylthioureido, di(C_{1-4} alkyl)thioureido, carboxy, (C_{1-6} alkoxy)carbonyl, and hydroxylamino;

or R^1 and R^2 together with the carbon atoms to which they are attached and the two carbon atoms through which the isoxazole and thiazole moieties of the core are joined form a fused C_{5-7} carbocyclyl group or fused 5-7 membered heterocyclyl group optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di $(C_{1-4}$ alkyl)amino, hydroxy, carboxy, $(C_{1-4}$ alkoxy)carbonyl, or cyano;

 R^3 is H or C_{1-6} alkyl;

R⁴, at each independent occurrence, is H or C₁₋₄ alkyl;

R⁵ and R⁹ are each, independently, H, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl, heteroaryl, C₃₋₇ cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, (C₃₋₇ cycloalkyl)alkyl or (5-7 membered heterocycloalkyl)alkyl;

alkyl)amino,

 R^6 and R^{10} are each, independently, H, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, heteroaryl, C_{3-7} cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, $(C_{3-7}$ cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, amino, $(C_{1-4}$ alkyl)amino, di $(C_{1-4}$

Docket No.: 74.US2.PCT

 R^7 and R^8 are each, independently, H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, heteroaryl, C_{3-7} cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, $(C_{3-7}$ cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, $(C_{1-8}$ alkyl)carbonyl, $(C_{1-8}$ haloalkyl)carbonyl, $(C_{1-8}$ haloalkyl)carbonyl, $(C_{1-8}$ haloalkoxy)carbonyl, $(C_{1-4}$ alkyl)sulfonyl, $(C_{1-4}$ haloalkyl)sulfonyl or arylsulfonyl;

or R⁷ and R⁸, together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group;

 R^{11} and R^{12} are each, independently, H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, heteroaryl, C_{3-7} cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, $(C_{3-7}$ cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, $(C_{1-8}$ alkyl)carbonyl, $(C_{1-8}$ haloalkyl)carbonyl, $(C_{1-8}$ haloalkyl)carbonyl, $(C_{1-8}$ haloalkoxy)carbonyl, $(C_{1-4}$ alkyl)sulfonyl, $(C_{1-4}$ haloalkyl)sulfonyl or arylsulfonyl;

or R¹¹ and R¹², together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group; and

R¹³ and R¹⁴ are each, independently, halo, cyano, nitro, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino, (C₁₋₄ alkyl)amino, di(C₁₋₄ alkyl)amino, hydroxy, carboxy, (C₁₋₄ alkoxy)carbonyl, C₁₋₄ acyl, C₁₋₄ acyloxy, aminocarbonyl, (C₁₋₄ alkyl)aminocarbonyl, or di(C₁₋₄ alkyl)aminocarbonyl.

2. (Original) The compound of claim 1 wherein Ar^1 is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar^1 is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl optionally substituted by one or more R^{13} , heterocyclyl optionally substituted by one or more R^{13} , carbocyclylalkyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkyl optionally substituted by one or more R^{13} , heterocyclylalkenyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, R^{13} , hydroxylamino, hydrox

Page 6 of 28

3. (Original) The compound of claim 1 wherein Ar¹ is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸.

- 4. (Original) The compound of claim 1 wherein Ar¹ is aryl, biaryl or heteroarylaryl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, carbocyclyl optionally substituted by one or more R¹³, heterocyclyl optionally substituted by one or more R¹³, carbocyclylalkyl optionally substituted by one or more R¹³, carbocyclylalkynyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸.
- 5. (Original) The compound of claim 1 wherein Ar^1 is phenyl, biphenyl or heteroarylphenyl, wherein Ar^1 is optionally substituted with one or more substituents selected from halo, cyano, nitro, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, carbocyclyl optionally substituted by one or more R^{13} , heterocyclyl optionally substituted by one or more R^{13} , carbocyclylalkyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, OR^5 , SR^5 , SOR^6 , SO_2R^6 , COR^6 , $COOR^5$, $OC(O)R^6$ or NR^7R^8 .
- 6. (Original) The compound of claim 1 wherein Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸.

Page 7 of 28

7. (Original) The compound of claim 1 wherein Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, C₁₋₄ alkoxy, SO₂R⁶, COR⁶, COOR⁵ or NR⁷R⁸.

Docket No.: 74.US2.PCT

- 8. (Original) The compound of claim 1 wherein Ar^2 is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl optionally substituted by one or more R^{14} , heterocyclyl optionally substituted by one or more R^{14} , hydroxylamino, OR^9 , SR^9 , SOR^{10} , SO_2R^{10} , COR^{10} , $COOR^9$, $OC(O)R^{10}$ or $NR^{11}R^{12}$.
- 9. (Original) The compound of claim 1 wherein Ar² is aryl or heteroaryl.
- 10. (Original) The compound of claim 1 wherein Ar² is heteroaryl.
- 11. (Original) The compound of claim 1 wherein Ar² is thienyl.
- 12. (Original) The compound of claim 1 wherein Ar² is aryl.
- 13. (Original) The compound of claim 1 wherein Ar² is phenyl.
- 14. (Original) The compound of claim 1 wherein D is CR³.
- 15. (Original) The compound of claim 1 wherein D is CH.
- 16. (Original) The compound of claim 1 wherein A^1 is a C_{1-3} alkylene group.
- 17. (Original) The compound of claim 1 wherein A¹ is CH₂ or CH₂CH₂.
- 18. (Original) The compound of claim 1 wherein A¹ is absent.
- 19. (Original) The compound of claim 1 wherein D is CR^3 and A^2 is a C_{1-3} alkylene group.
- 20. (Original) The compound of claim 1 wherein D is CR³ and A² is CH₂CH₂ or CH₂CH₂CH₂.

Page 8 of 28

21. (Original) The compound of claim 1 wherein D is CR³, A¹ is CH₂CH₂, and A² is CH₂CH₂.

- 22. (Original) The compound of claim 1 wherein D is CR³, A¹ is absent, and A² is CH₂CH₂CH₂.
- 23. (Original) The compound of claim 1 wherein E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond.
- 24. (Original) The compound of claim 1 wherein E is CO or SO₂.
- 25. (Original) The compound of claim 1 wherein E is CO.
- 26. (Original) The compound of claim 1 wherein G is C_{1-3} alkylene.
- 27. (Original) The compound of claim 1 wherein G is CH₂ or CH₂CH₂.
- 28. (Original) The compound of claim 1 wherein G is CH₂.
- 29. (Original) The compound of claim 1 wherein R^1 is H or C_{1-4} alkyl.
- 30. (Original) The compound of claim 1 wherein R¹ is methyl.
- 31. (Original) The compound of claim 1 wherein:

 R^1 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^1 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)aminocarbonyl, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfinyl, C_{1-4} haloalkylsulfonyl, aminosulfonyl, (C_{1-4} alkyl)aminosulfonyl, di(C_{1-4} alkyl)aminosulfonyl, ureido, C_{1-4} alkylureido, di(C_{1-4} alkyl)ureido, thioureido, C_{1-4} alkylthioureido, di(C_{1-4} alkyl)thioureido, carboxy, (C_{1-6} alkoxy)carbonyl, and hydroxylamino; and

 R^2 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^2 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di $(C_{1-4}$ alkyl)amino, aminocarbonyl, $(C_{1-4}$ alkyl)aminocarbonyl, $(C_{1-4}$

Page 9 of 28

alkylsulfonyl, C_{1-4} haloalkylsulfinyl, C_{1-4} haloalkylsulfonyl, aminosulfonyl, $(C_{1-4}$ alkyl)aminosulfonyl, di $(C_{1-4}$ alkyl)aminosulfonyl, ureido, C_{1-4} alkylureido, di $(C_{1-4}$ alkyl)ureido, thioureido, C_{1-4} alkylthioureido, di $(C_{1-4}$ alkyl)thioureido, carboxy, $(C_{1-6}$ alkoxy)carbonyl, and hydroxylamino.

- 32. (Original) The compound of claim 1 wherein R^2 is H or C_{1-4} alkyl.
- 33. (Original) The compound of claim 1 wherein R² is H.
- 34. (Original) The compound of claim 1 wherein R³ is H.
- 35. (Original) The compound of claim 1 wherein R⁴, at each independent occurrence, is H.
- 36. (Original) The compound of claim 1 wherein:

D is CR³;

 A^1 is a absent or a C_{1-3} alkylene group;

 A^2 is a C_{1-3} alkylene group;

E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond;

G is C₁₋₃ alkylene;

 R^1 is H or C_{1-6} alkyl; and

 R^2 is H or C_{1-6} alkyl.

37. (Original) The compound of claim 1 wherein:

Ar² is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, carbocyclyl optionally substituted by one or more R¹⁴, heterocyclyl optionally substituted by one or more R¹⁴, hydroxylamino, OR⁹, SR⁹, SOR¹⁰, SO₂R¹⁰, COR¹⁰, COOR⁹, OC(O)R¹⁰ or NR¹¹R¹²;

D is CR³;

 A^1 is absent or a C_{1-3} alkylene group;

 A^2 is a C_{1-3} alkylene group;

E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond;

G is C₁₋₃ alkylene;

 R^1 is H or C_{1-6} alkyl; and

 R^2 is H or C_{1-6} alkyl.

Page 10 of 28

38. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, carbocyclyl optionally substituted by one or more R^{13} , heterocyclyl optionally substituted by one or more R^{13} , carbocyclylalkyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkyl optionally substituted by one or more R^{13} , heterocyclylalkyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, OR^5 , SR^5 , SOR^6 , SO_2R^6 , COR^6 , $COOR^5$, $OC(O)R^6$ or NR^7R^8 ;

Docket No.: 74.US2.PCT

```
Ar<sup>2</sup> is aryl or heteroaryl;
D is CR<sup>3</sup>;
A<sup>1</sup> is absent or a C<sub>1-3</sub> alkylene group;
A<sup>2</sup> is a C<sub>1-3</sub> alkylene group;
E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;
G is C<sub>1-3</sub> alkylene;
R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and
R<sup>2</sup> is H or C<sub>1-6</sub> alkyl.
```

39. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸;

```
Ar<sup>2</sup> is aryl or heteroaryl;
D is CR<sup>3</sup>;
A<sup>1</sup> is absent or a C<sub>1-3</sub> alkylene group;
A<sup>2</sup> is a C<sub>1-3</sub> alkylene group;
E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;
G is C<sub>1-3</sub> alkylene;
R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and
R<sup>2</sup> is H or C<sub>1-6</sub> alkyl.
```

Page 11 of 28

40. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸;

Ar² is aryl or heteroaryl;
D is CH;
A¹ is absent, CH₂ or CH₂CH₂;
A² is CH₂CH₂ or CH₂CH₂CH₂;
E is CO, SO₂ or a bond;
G is CH₂ or CH₂CH₂;
R¹ is C₁₋₄ alkyl; and
R² is H.

41. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, C₁₋₄ alkoxy, SO₂R⁶, COR⁶, COOR⁵ or NR⁷R⁸;

Ar² is aryl or heteroaryl;
D is CH;
A¹ is absent, CH₂ or CH₂CH₂;
A² is CH₂CH₂ or CH₂CH₂CH₂;
E is CO, SO₂ or a bond;
G is CH₂ or CH₂CH₂;
R¹ is C₁₋₄ alkyl; and
R² is H.

42. (Original) The compound of claim 1 selected from:

Docket No.: 74.US2.PCT

- 4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-1-phenylmethane-sulfonyl-piperidine;
- 1-(4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-(4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-3-yl-ethanone;
- 1-(2-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-pyrrolidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-(4-{4-[3-(3-Isopropylamino-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(2-morpholin-4-yl-ethylamino)-phenyl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- 1-(4-{4-[5-Methyl-3-(3-morpholin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(4-methyl-piperazin-1-yl)-phenyl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-yl]-acetamide;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-yl]-acetamide;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid amide;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-carboxylic acid amide;
- 3'-{5-Methyl-4-[2-(1-phenylmethanesulfonyl-piperidin-4-yl)-thiazol-4-yl]-isoxazol-3-yl}-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-pyrrolidin-2-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-carboxylic acid;
- 1-(4-{4-[5-Methyl-3-(3-pyridin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

Page 13 of 28

1-(4-{4-[5-Methyl-3-(3-pyrimidin-5-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

1-(4-{4-[3-(4'-Methoxy-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid dimethylamide;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid methylamide;

1-[4-(4-{5-Methyl-3-[4'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

1-[4-(4-{5-Methyl-3-[3'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

1-(4-{4-[3-(4'-Amino-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-yl]-methanesulfonamide;

1-(4-{4-[3-(4'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

2,2,2-Trifluoro-N-[3'-(5-methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-yl]-acetamide;

1-(4-{4-[3-(3'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carbonitrile;

1-{4-[4-(3-{3-[3-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl}-5-methyl-isoxazol-4-yl)-thiazol-2-yl]-piperidin-1-yl}-2-thiophen-2-yl-ethanone;

1-[4-(4-{5-Methyl-3-[4'-(1H-tetrazol-5-yl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone; and

 $1-[4-(4-\{3-[4'-(4,5-Dihydro-1H-imidazol-2-yl)-biphenyl-3-yl]-5-methyl-isoxazol-4-yl\}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;$

or pharmaceutically acceptable salt thereof.

Page 14 of 28

43. (Original) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

- 44. (Original) A method of modulating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1.
- 45. (Amended) A method of activating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1 or 42.
- 46. (Original) A method of increasing the adenylyl cyclase activity or the level of 5'-monophosphate (cAMP) in a cell, cell culture or tissue expressing the follicle stimulating hormone receptor comprising contacting said cell, cell culture or tissue with a compound of claim 1.
- 47. (Original) A method of inducing ovulation in a female mammal comprising administering to said female mammal an ovulation-inducing amount of a compound of claim 1.
- 48. (Amended) A method of treating a fertility disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 or 42.
- 49. (Original) A method of treating infertility in a female patient comprising administering to said female patient a therapeutically effective amount of a compound of claim 1.
- 50. (Cancelled) A compound according to any one of claims 1 to 42 for use in therapy.
- 51. (Cancelled) A compound according to any one of claims 1 to 42 for use in the treatment of a fertility disorder in a patient.
- 52. (Cancelled) A compound according to any one of claims 1 to 42 for use in the treatment of infertility in a female patient.
- 53. (Cancelled) A compound according to any one of claims 1 to 42 for use in the preparation of a medicament for use in therapy.

Page 15 of 28

54. (Cancelled) A compound according to any one of claims 1 to 42 for use in the preparation of a medicament for use in the treatment of a fertility disorder in a patient.

- 55. (Cancelled) A compound according to any one of claims 1 to 42 for use in the preparation of a medicament for use in the treatment of infertility in a female patient.
- 56. (Cancelled) Use of a compound according to any one of claims 1 to 42 for the manufacture of a medicament.
- 57. (Cancelled) Use of a compound according to any one of claims 1 to 42 for the manufacture of a medicament for the treatment of a fertility disorder in a patient.
- 58. (Cancelled) Use of a compound according to any one of claims 1 to 42 for the manufacture of a medicament for the treatment of infertility in a female patient.

Page 16 of 28

Clean Copy of Claims:

1. (Original) A compound of Formula I:

$$R^1$$
 R^2
 R^2
 R^2
 R^3
 R^4
 R^4
 R^4
 R^4
 R^4
 R^2
 R^4
 R^4

Docket No.: 74.US2.PCT

or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:

Ar¹ is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl optionally substituted by one or more R^{13} , heterocyclyl optionally substituted by one or more R^{13} , carbocyclylalkyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkyl optionally substituted by one or more R^{13} , heterocyclylalkenyl optionally substituted by one or more R^{13} , heterocyclylalkenyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally substituted by one or more R^{13} , hoterocyclylalkynyl optionally subs

Ar² is aryl or heteroaryl, each optionally substituted with one or more substituents selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl optionally substituted by one or more R^{14} , heterocyclyl optionally substituted by one or more R^{14} , hydroxylamino, OR^9 , SR^9 , SOR^{10} , SO_2R^{10} , COR^{10} , $COOR^9$, $OC(O)R^{10}$ or $NR^{11}R^{12}$;

D is N, C or CR³;

--- is a single bond when D is N or CR³;

--- is a double bond when D is C;

 A^1 is absent or a C_{1-3} straight-chain aliphatic group optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, (C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino, hydroxy, carboxy, (C_{1-4} alkoxy)carbonyl, or cyano;

 A^2 is C_{1-4} straight-chain aliphatic group optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-6}$ alkyl)amino, hydroxy, carboxy, $(C_{1-4}$ alkoxy)carbonyl, or cyano;

E is CO, C(O)O, C(O)NR⁴, NR⁴CONR⁴, SO, SO₂, SONR⁴, SO₂NR⁴, or a bond;

Docket No.: 74.US2.PCT

G is C_{1-3} alkylene, C_{2-3} alkenylene or C_{2-3} alkynylene optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di $(C_{1-4}$ alkyl)amino, hydroxy, carboxy, $(C_{1-4}$ alkoxy)carbonyl, or cyano;

 R^1 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^1 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di(C_{1-4} alkyl)amino, aminocarbonyl, $(C_{1-4}$ alkyl)aminocarbonyl, $(C_{1-4}$ alkyl)aminocarbonyl, $(C_{1-4}$ alkylsulfinyl, $(C_{1-4}$ alkyl)aminosulfonyl, aminosulfonyl, $(C_{1-4}$ alkyl)aminosulfonyl, di($(C_{1-4}$ alkyl)aminosulfonyl, ureido, $(C_{1-4}$ alkyl)ureido, thioureido, $(C_{1-4}$ alkyl)aminosulfonyl, and hydroxylamino;

 R^2 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^2 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di(C_{1-4} alkyl)amino, aminocarbonyl, $(C_{1-4}$ alkyl)aminocarbonyl, $(C_{1-4}$ alkyl)aminocarbonyl, $(C_{1-4}$ alkylsulfinyl, $(C_{1-4}$ alkylsulfinyl, $(C_{1-4}$ alkyl)aminosulfonyl, aminosulfonyl, $(C_{1-4}$ alkyl)aminosulfonyl, di($(C_{1-4}$ alkyl)aminosulfonyl, ureido, $(C_{1-4}$ alkyl)ureido, thioureido, $(C_{1-4}$ alkyl)aminosulfonyl, and hydroxylamino;

or R^1 and R^2 together with the carbon atoms to which they are attached and the two carbon atoms through which the isoxazole and thiazole moieties of the core are joined form a fused C_{5-7} carbocyclyl group or fused 5-7 membered heterocyclyl group optionally substituted with one or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di $(C_{1-4}$ alkyl)amino, hydroxy, carboxy, $(C_{1-4}$ alkoxy)carbonyl, or cyano;

 R^3 is H or C_{1-6} alkyl;

R⁴, at each independent occurrence, is H or C₁₋₄ alkyl;

 R^5 and R^9 are each, independently, H, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, heteroaryl, C_{3-7} cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, $(C_{3-7}$ cycloalkyl)alkyl or (5-7 membered heterocycloalkyl)alkyl;

R⁶ and R¹⁰ are each, independently, H, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl, heteroaryl, C₃₋₇ cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, (C₃₋₇ cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, amino, (C₁₋₄ alkyl)amino, di(C₁₋₄ alkyl)amino,

Page 18 of 28

 R^7 and R^8 are each, independently, H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, heteroaryl, C_{3-7} cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, $(C_{3-7}$ cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, $(C_{1-8}$ alkyl)carbonyl, $(C_{1-8}$ haloalkyl)carbonyl, $(C_{1-8}$ haloalkyl)carbonyl, $(C_{1-8}$ haloalkoxy)carbonyl, $(C_{1-4}$ alkyl)sulfonyl, $(C_{1-4}$ haloalkyl)sulfonyl or arylsulfonyl;

Docket No.: 74.US2.PCT

or R⁷ and R⁸, together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group;

 R^{11} and R^{12} are each, independently, H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, heteroaryl, C_{3-7} cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, $(C_{3-7}$ cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, $(C_{1-8}$ alkyl)carbonyl, $(C_{1-8}$ haloalkyl)carbonyl, $(C_{1-8}$ haloalkoxy)carbonyl, $(C_{1-8}$ haloalkoxy)carbonyl, $(C_{1-4}$ alkyl)sulfonyl, $(C_{1-4}$ haloalkyl)sulfonyl or arylsulfonyl;

or R¹¹ and R¹², together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group; and

 R^{13} and R^{14} are each, independently, halo, cyano, nitro, C_{14} alkyl, C_{14} haloalkyl, C_{14} alkoxy, C_{14} haloalkoxy, amino, $(C_{14}$ alkyl)amino, di $(C_{14}$ alkyl)amino, hydroxy, carboxy, $(C_{14}$ alkoxy)carbonyl, C_{14} acyl, C_{14} acyloxy, aminocarbonyl, $(C_{14}$ alkyl)aminocarbonyl, or di $(C_{14}$ alkyl)aminocarbonyl.

- 2. (Original) The compound of claim 1 wherein Ar^1 is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar^1 is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl optionally substituted by one or more R^{13} , heterocyclyl optionally substituted by one or more R^{13} , carbocyclylalkyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkyl optionally substituted by one or more R^{13} , heterocyclylalkyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, R^{13} , hydroxylamino, hyd
- 3. (Original) The compound of claim 1 wherein Ar¹ is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally

Page 19 of 28

substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸.

Docket No.: 74.US2.PCT

- 4. (Original) The compound of claim 1 wherein Ar¹ is aryl, biaryl or heteroarylaryl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, carbocyclyl optionally substituted by one or more R¹³, heterocyclyl optionally substituted by one or more R¹³, carbocyclylalkyl optionally substituted by one or more R¹³, carbocyclylalkynyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸.
- 5. (Original) The compound of claim 1 wherein Ar^1 is phenyl, biphenyl or heteroarylphenyl, wherein Ar^1 is optionally substituted with one or more substituents selected from halo, cyano, nitro, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, carbocyclyl optionally substituted by one or more R^{13} , heterocyclyl optionally substituted by one or more R^{13} , carbocyclylalkyl optionally substituted by one or more R^{13} , carbocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , hydroxylamino, R^{13} , hydroxylamino, R^{13} , some substituted by R^{13} , hydroxylamino, R^{13} , hydroxylamino, R^{13} , some substituted by R^{13} , hydroxylamino, R^{13} , hydroxylamino, R^{13} , hydroxylamino, some substituted by subs
- 6. (Original) The compound of claim 1 wherein Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸.
- 7. (Original) The compound of claim 1 wherein Ar^1 is phenyl, biphenyl or heteroarylphenyl, wherein Ar^1 is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , C_{1-4} alkoxy, SO_2R^6 , COR^6 , $COOR^5$ or NR^7R^8 .

Page 20 of 28

8. (Original) The compound of claim 1 wherein Ar^2 is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, carbocyclyl optionally substituted by one or more R^{14} , heterocyclyl optionally substituted by one or more R^{14} , hydroxylamino, OR^9 , SR^9 , SOR^{10} , SO_2R^{10} , COR^{10} , COR^{10} , COR^9 , $OC(O)R^{10}$ or $NR^{11}R^{12}$.

Docket No.: 74.US2.PCT

- 9. (Original) The compound of claim 1 wherein Ar² is aryl or heteroaryl.
- 10. (Original) The compound of claim 1 wherein Ar² is heteroaryl.
- 11. (Original) The compound of claim 1 wherein Ar² is thienyl.
- 12. (Original) The compound of claim 1 wherein Ar² is aryl.
- 13. (Original) The compound of claim 1 wherein Ar² is phenyl.
- 14. (Original) The compound of claim 1 wherein D is CR³.
- 15. (Original) The compound of claim 1 wherein D is CH.
- 16. (Original) The compound of claim 1 wherein A^1 is a C_{1-3} alkylene group.
- 17. (Original) The compound of claim 1 wherein A¹ is CH₂ or CH₂CH₂.
- 18. (Original) The compound of claim 1 wherein A¹ is absent.
- 19. (Original) The compound of claim 1 wherein D is CR^3 and A^2 is a C_{1-3} alkylene group.
- 20. (Original) The compound of claim 1 wherein D is CR³ and A² is CH₂CH₂ or CH₂CH₂CH₂.
- 21. (Original) The compound of claim 1 wherein D is CR³, A¹ is CH₂CH₂, and A² is CH₂CH₂.
- 22. (Original) The compound of claim 1 wherein D is CR³, A¹ is absent, and A² is CH₂CH₂CH₂.

Page 21 of 28

23. (Original) The compound of claim 1 wherein E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond.

Docket No.: 74.US2.PCT

- 24. (Original) The compound of claim 1 wherein E is CO or SO₂.
- 25. (Original) The compound of claim 1 wherein E is CO.
- 26. (Original) The compound of claim 1 wherein G is C_{1-3} alkylene.
- 27. (Original) The compound of claim 1 wherein G is CH₂ or CH₂CH₂.
- 28. (Original) The compound of claim 1 wherein G is CH₂.
- 29. (Original) The compound of claim 1 wherein R^1 is H or C_{1-4} alkyl.
- 30. (Original) The compound of claim 1 wherein R¹ is methyl.

31. (Original) The compound of claim 1 wherein:

 R^1 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^1 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)aminocarbonyl, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfinyl, C_{1-4} haloalkylsulfonyl, aminosulfonyl, (C_{1-4} alkyl)aminosulfonyl, di(C_{1-4} alkyl)aminosulfonyl, ureido, C_{1-4} alkylureido, di(C_{1-4} alkyl)ureido, thioureido, C_{1-4} alkylthioureido, di(C_{1-4} alkyl)thioureido, carboxy, (C_{1-6} alkoxy)carbonyl, and hydroxylamino; and

 R^2 is H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, wherein R^2 is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C_{1-4} haloalkyl, C_{1-5} acyl, C_{1-5} acyloxy, C_{1-4} alkoxy, C_{1-4} thioalkoxy, C_{1-4} haloalkoxy, amino, $(C_{1-4}$ alkyl)amino, di(C_{1-4} alkyl)amino, aminocarbonyl, $(C_{1-4}$ alkyl)aminocarbonyl, $(C_{1-4}$ alkyl)aminocarbonyl, $(C_{1-4}$ alkylsulfinyl, $(C_{1-4}$ alkyl)aminosulfonyl, aminosulfonyl, $(C_{1-4}$ alkyl)aminosulfonyl, di($(C_{1-4}$ alkyl)aminosulfonyl, ureido, $(C_{1-4}$ alkyl)ureido, thioureido, $(C_{1-4}$ alkyl)aminosulfonyl, and hydroxylamino.

Page 22 of 28

32. (Original) The compound of claim 1 wherein R^2 is H or C_{1-4} alkyl.

- 33. (Original) The compound of claim 1 wherein R² is H.
- 34. (Original) The compound of claim 1 wherein R³ is H.
- 35. (Original) The compound of claim 1 wherein R⁴, at each independent occurrence, is H.

Docket No.: 74.US2.PCT

36. (Original) The compound of claim 1 wherein:

D is CR³;

 A^1 is a absent or a C_{1-3} alkylene group;

 A^2 is a C_{1-3} alkylene group;

E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond;

G is C₁₋₃ alkylene;

 R^1 is H or C_{1-6} alkyl; and

 R^2 is H or C_{1-6} alkyl.

37. (Original) The compound of claim 1 wherein:

Ar² is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, carbocyclyl optionally substituted by one or more R¹⁴, heterocyclyl optionally substituted by one or more R¹⁴, hydroxylamino, OR⁹, SR⁹, SOR¹⁰, SO₂R¹⁰, COR¹⁰, COOR⁹, OC(O)R¹⁰ or NR¹¹R¹²;

D is CR^3 ;

 A^1 is absent or a C_{1-3} alkylene group;

 A^2 is a C_{1-3} alkylene group;

E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond;

G is C₁₋₃ alkylene;

 R^1 is H or C_{1-6} alkyl; and

 R^2 is H or C_{1-6} alkyl.

38. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with one or more substituents selected from halo, cyano, nitro, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-

Page 23 of 28

C₆ alkynyl, carbocyclyl optionally substituted by one or more R¹³, heterocyclyl optionally substituted by one or more R¹³, carbocyclylalkyl optionally substituted by one or more R¹³, carbocyclylalkynyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸;

Docket No.: 74.US2.PCT

Ar² is aryl or heteroaryl;
D is CR³;
A¹ is absent or a C₁₋₃ alkylene group;
A² is a C₁₋₃ alkylene group;
E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond;
G is C₁₋₃ alkylene;
R¹ is H or C₁₋₆ alkyl; and
R² is H or C₁₋₆ alkyl.

39. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸;

Ar² is aryl or heteroaryl;
D is CR³;
A¹ is absent or a C₁₋₃ alkylene group;
A² is a C₁₋₃ alkylene group;
E is CO, C(O)O, C(O)NR⁴, SO₂ or a bond;
G is C₁₋₃ alkylene;
R¹ is H or C₁₋₆ alkyl; and
R² is H or C₁₋₆ alkyl.

40. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R¹³, heterocyclylalkyl optionally substituted by one or more R¹³, heterocyclylalkenyl optionally

Page 24 of 28

substituted by one or more R¹³, heterocyclylalkynyl optionally substituted by one or more R¹³, hydroxylamino, OR⁵, SR⁵, SOR⁶, SO₂R⁶, COR⁶, COOR⁵, OC(O)R⁶ or NR⁷R⁸;

Ar² is aryl or heteroaryl;

D is CH;

A¹ is absent, CH₂ or CH₂CH₂;

A² is CH₂CH₂ or CH₂CH₂CH₂;

E is CO, SO₂ or a bond;

G is CH₂ or CH₂CH₂;

R¹ is C₁₋₄ alkyl; and

 R^2 is H.

41. (Original) The compound of claim 1 wherein:

Ar¹ is phenyl, biphenyl or heteroarylphenyl, wherein Ar¹ is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R^{13} , heterocyclylalkynyl optionally substituted by one or more R^{13} , C_{1-4} alkoxy, SO_2R^6 , COR^6 , $COOR^5$ or NR^7R^8 ;

Ar² is aryl or heteroaryl;

D is CH;

A¹ is absent, CH₂ or CH₂CH₂;

A² is CH₂CH₂ or CH₂CH₂CH₂;

E is CO, SO₂ or a bond;

G is CH₂ or CH₂CH₂;

 R^1 is C_{1-4} alkyl; and

 R^2 is H.

42. (Original) The compound of claim 1 selected from:

- 4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-1-phenylmethanesulfonyl-piperidine;
- 1-(4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2thiophen-2-yl-ethanone;
- 1-(4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2thiophen-3-yl-ethanone;
- 1-(2-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-pyrrolidin-1-yl)-2thiophen-2-yl-ethanone;
- 1-(4-{4-[3-(3-Isopropylamino-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(2-morpholin-4-yl-ethylamino)-phenyl]-isoxazol-4-yl}-thiazol-2yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- 1-(4-{4-[5-Methyl-3-(3-morpholin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(4-methyl-piperazin-1-yl)-phenyl]-isoxazol-4-yl}-thiazol-2-yl)piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3yl)-biphenyl-4-yl]-acetamide;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3yl)-biphenyl-3-yl]-acetamide;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)biphenyl-4-carboxylic acid amide;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)biphenyl-3-carboxylic acid amide;
- 3'-{5-Methyl-4-[2-(1-phenylmethanesulfonyl-piperidin-4-yl)-thiazol-4-yl]-isoxazol-3yl}-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3yl)-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-pyrrolidin-2-yl]-thiazol-4-yl}-isoxazol-3yl)-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)biphenyl-3-carboxylic acid;
- 1-(4-{4-[5-Methyl-3-(3-pyridin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2thiophen-2-yl-ethanone;

Page 26 of 28

1-(4-{4-[5-Methyl-3-(3-pyrimidin-5-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

Docket No.: 74.US2.PCT

1-(4-{4-[3-(4'-Methoxy-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid dimethylamide;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid methylamide;

1-[4-(4-{5-Methyl-3-[4'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

1-[4-(4-{5-Methyl-3-[3'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

1-(4-{4-[3-(4'-Amino-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-yl]-methanesulfonamide;

1-(4-{4-[3-(4'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

2,2,2-Trifluoro-N-[3'-(5-methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-yl]-acetamide;

1-(4-{4-[3-(3'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carbonitrile;

1-{4-[4-(3-{3-[3-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl}-5-methyl-isoxazol-4-yl)-thiazol-2-yl]-piperidin-1-yl}-2-thiophen-2-yl-ethanone;

1-[4-(4-{5-Methyl-3-[4'-(1H-tetrazol-5-yl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone; and

1-[4-(4-{3-[4'-(4,5-Dihydro-1H-imidazol-2-yl)-biphenyl-3-yl]-5-methyl-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

or pharmaceutically acceptable salt thereof.

43. (Original) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Page 27 of 28

44. (Original) A method of modulating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1.

- 45. (Amended) A method of activating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1 or 42.
- 46. (Original) A method of increasing the adenylyl cyclase activity or the level of 5'-monophosphate (cAMP) in a cell, cell culture or tissue expressing the follicle stimulating hormone receptor comprising contacting said cell, cell culture or tissue with a compound of claim 1.
- 47. (Original) A method of inducing ovulation in a female mammal comprising administering to said female mammal an ovulation-inducing amount of a compound of claim 1.
- 48. (Amended) A method of treating a fertility disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 or 42.
- 49. (Original) A method of treating infertility in a female patient comprising administering to said female patient a therapeutically effective amount of a compound of claim 1.